Acute Myeloid Leukemia
Conditions
Interventions
Case series:Nil
Sponsors
the First Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Retrospective study: 1) subjects with acute myeloid leukemia (AML) diagnosed to the WHO AML classification (2016); 2) received an allo-geneic HSCT before May 2018; 3) with the results of MICM at the time of diagnosis; 4) with the gene mutation results of NGS at diagnosis and pre-HSCT; Prospective study: 1) male or female patients aged 18 years or old; 2) subjects with acute myeloid leukemia (AML) diagnosed to the WHO AML classification (2016); 3) MICM examination and NGS was performed at the time of diagnosis; 4) agree to participate in this study and sign the informed consent form; 5) anticipated to receive an allo-geneic HSCT within 30 days.
Exclusion criteria
Exclusion criteria: 1) history of another active malignancy; 2) pregnant women, women planning to become pregnant, or women who are breast feeding should not participate in the study; 3) other situations which, in the judgment of the investigator, would make the patient inappropriate for entry into this study; 4) Recruitment in other clinical trials which could have an effect on this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the prognostic impact of molecular residual disease by using NGS on the relapse rate in a cohort of AML patients receiving allo-HSCT; | — |
Countries
China
Contacts
Public ContactDepei Wu
the First Affiliated Hospital of Soochow University
Outcome results
None listed